KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End

KM Biologics President Toshiaki Nagasato KM Biologics President Toshiaki Nagasato revealed on October 25 that the company aims to file its investigational COVID-19 vaccine KD-414 in Japan between next spring and summer, seeking conditional early approval initially for its use...read more